Lucid Diligence Brief: CorriXR × InhaTarget × Merxin, inhaled CRISPR therapy for lung cancer
Lucid Diligence Brief: CorriXR × InhaTarget × Merxin, inhaled CRISPR therapy…
Lucid Diligence Brief: Circular Genomics $15 million Series A for circular RNA biomarkers
Lucid Diligence Brief: Circular Genomics $15 million Series A for circular RNA…
Lucid Diligence Brief: Regeneron and Tessera team on TSRA-196 for AATD
Lucid Diligence Brief: Regeneron and Tessera team on TSRA-196 for AATD…
AI in Healthcare and Digital Health Video Recap —December 2, 2025
Here’s your biweekly AI in Healthcare and Digital Health video brief covering…
Lucid Diligence Brief: Protego Biopharma $130M Series B
Lucid Diligence Brief: Protego Biopharma $130M Series B Professional audiences…
AI in Healthcare and Digital Health Today—December 1, 2025
This week's AI in Healthcare and Digital Health update highlights…
Lucid Diligence Brief: Dayra Therapeutics, Versant Ventures and Biogen collaboration
Lucid Diligence Brief: Dayra Therapeutics, Versant Ventures and Biogen…
Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer
Lucid Diligence Brief: Zetagen $12.9 million Series B1 in breast cancer…
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration Professional…
Lucid Diligence Brief: Waker BioScience Series A in CGT
Lucid Diligence Brief: Waker BioScience Series A in CGT Professional audiences…
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+ Professional audiences…
Lucid Diligence Brief: Sword Health partners with Greece on AI health "front door"
Lucid Diligence Brief: Sword Health partners with Greece on AI health "front…